Collect Data From Patients Receiving Standardized Anti-tuberculosis Therapy, Collect Monitoring Data, and Evaluate Treatment Efficacy and Potential Adverse Reactions.

Clinical Study on the Correlation Between Plasma Concentrations of Antituberculosis Drugs and Treatment Efficacy/Safety.

The purpose of this clinical trial is to investigate the correlation between anti-tuberculosis drug concentration monitoring and treatment efficacy and safety through analytical studies.The main questions it aims to answer include:

Guidance for individualized dosage adjustment of anti-tuberculosis drugs; Guidance on medication challenges for special populations and patients with comorbidities;Address the dose optimization issue for refractory tuberculosis.

Inclusion Criteria:

• Patients with tuberculosis confirmed by bacteriological or pathological diagnosis;
• Those who have received standardized anti-tuberculosis treatment regimens;
• Patients with complete clinical records and completed follow-up for at least one treatment course.

Exclusion Criteria:

• Baseline alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels>2 times the upper limit of normal;
• Concurrent chronic liver diseases such as chronic hepatitis B, hepatitis C, or alcoholic liver disease;
• Concurrent severe underlying cardiac conditions (e.g.,congenital heart disease, cardiomyopathy, severe arrhythmias);
• Concurrent use of multiple medications that may affect cardiac function;
• Human immunodeficiency virus (HIV) co-infection;
• Women who are pregnant or breastfeeding.